Minerva Neurosciences Inc (NASDAQ:NERV) – Research analysts at Jefferies Group increased their FY2018 EPS estimates for shares of Minerva Neurosciences in a research note issued on Monday. Jefferies Group analyst B. Amin now expects that the biopharmaceutical company will post earnings per share of ($1.46) for the year, up from their previous forecast of ($1.50). Jefferies Group also issued estimates for Minerva Neurosciences’ FY2019 earnings at ($1.50) EPS, FY2020 earnings at ($1.79) EPS and FY2021 earnings at ($1.44) EPS.
Several other equities research analysts have also recently commented on the stock. ValuEngine cut shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $12.92.
Shares of Minerva Neurosciences (NERV) opened at $6.45 on Thursday. Minerva Neurosciences has a 1 year low of $4.80 and a 1 year high of $11.15.
Large investors have recently modified their holdings of the company. Nationwide Fund Advisors grew its position in shares of Minerva Neurosciences by 14.2% during the 2nd quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,616 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Minerva Neurosciences by 38.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,359 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 6,251 shares during the period. Trexquant Investment LP acquired a new stake in shares of Minerva Neurosciences during the 3rd quarter worth approximately $189,000. New York State Common Retirement Fund grew its position in shares of Minerva Neurosciences by 62.4% during the 2nd quarter. New York State Common Retirement Fund now owns 28,100 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 10,799 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Minerva Neurosciences by 47.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 13,199 shares during the period. Institutional investors own 70.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokers Offer Predictions for Minerva Neurosciences Inc’s FY2018 Earnings (NERV)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/15/brokers-offer-predictions-for-minerva-neurosciences-incs-fy2018-earnings-nerv.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.